Reduces risk for heart failure and cardiovascular disease hospitalizations.
The recalls of a widely used hypertension blood drug due to carcinogenic impurities are expanding.
A pharma maker is voluntarily recalling several lots of a major heart medication. Here’s why.
FDA declined to approve Merck’s claim that its cholesterol-lowering drugs Zetia and Vytorin reduce the risk of heart attacks and strokes in patients with coronary heart disease.
An FDA review of safety studies suggests a slightly increased risk of problems involving the heart and blood vessels supplying the brain among patients being treated with the asthma drug omalizumab (Xolair, Genentech) than in those who were not treated with omalizumab. As a result, FDA has added information about these potential risks to the drug label.